A multicenter research effort yielded findings that may allow for more effective and personalized treatment of an underrecognized but serious blood disorder.Extended follow-up of individuals with ...
Onvuzosiran achieved significant and durable reductions of plasma kallikrein levels with a favorable safety profile in Phase 1/2 – SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, ...
Alzheimer's disease researchers say they've built a method using simple blood tests to predict if and when someone may show ...
A diagnosis of serious liver disease can feel like a slow countdown. Scar tissue builds quietly, the liver stiffens, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results